The stock of Codexis, Inc. (NASDAQ:CDXS) is a huge mover today! The stock increased 3.98% or $0.17 during the last trading session, hitting $4.44. About 104,244 shares traded hands or 39.40% up from the average. Codexis, Inc. (NASDAQ:CDXS) has risen 4.91% since February 26, 2016 and is uptrending. It has underperformed by 5.51% the S&P500.
The move comes after 8 months positive chart setup for the $177.04 million company. It was reported on Oct, 1 by Barchart.com. We have $12.88 PT which if reached, will make NASDAQ:CDXS worth $336.38 million more.
Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on November, 2. They expect $-0.14 EPS, down 207.69% or $0.27 from last year’s $0.13 per share. After $0.07 actual EPS reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -300.00% negative EPS growth.
According to Zacks Investment Research, “Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.”
Insitutional Activity: The institutional sentiment increased to 1.42 in 2016 Q2. Its up 0.34, from 1.08 in 2016Q1. The ratio improved, as 14 funds sold all Codexis, Inc. shares owned while 12 reduced positions. 20 funds bought stakes while 17 increased positions. They now own 16.51 million shares or 13.83% more from 14.50 million shares in 2016Q1.
Nationwide Fund Advsrs owns 20,988 shares or 0% of their US portfolio. Credit Suisse Ag holds 15,043 shares or 0% of its portfolio. Amer International Incorporated has 0% invested in the company for 19,272 shares. Tiaa Cref Investment Mgmt Ltd Liability Com, a New York-based fund reported 103,482 shares. Goldman Sachs Group Incorporated last reported 16,937 shares in the company. Blackrock Fund has 876,101 shares for 0% of their US portfolio. National Bank & Trust Of Montreal Can reported 201 shares or 0% of all its holdings. Legal & General Group Inc Pcl holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 6,312 shares. Northern Tru Corp owns 347,068 shares or 0% of their US portfolio. Moreover, Menta Cap Ltd Company has 0.02% invested in Codexis, Inc. (NASDAQ:CDXS) for 39,878 shares. Jacobs Levy Equity Mgmt accumulated 0% or 16,629 shares. Dimensional Fund Ltd Partnership holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 65,695 shares. Manufacturers Life Com The accumulated 0% or 28,751 shares. Walleye Trading Lc, a Minnesota-based fund reported 1,123 shares. Mufg Americas Corp accumulated 1,282 shares or 0% of the stock.
Insider Transactions: Since August 3, 2016, the stock had 0 insider buys, and 5 sales for $1.31 million net activity. VIVO VENTURES VII – LLC sold $474,624 worth of stock or 111,600 shares. The insider KELLEY BERNARD J sold 12,643 shares worth $53,807. On Friday, August 26 the insider WOLF DENNIS P sold $75,974.
More important recent Codexis, Inc. (NASDAQ:CDXS) news were published by: Marketwatch.com which released: “Codexis Inc.” on April 22, 2010, also Seekingalpha.com published article titled: “Can Codexis Maintain Its Clout?”, Finance.Yahoo.com published: “Codexis to Present at September Investment Conferences” on September 06, 2016. More interesting news about Codexis, Inc. (NASDAQ:CDXS) was released by: Businesswire.com and their article: “Codexis Files Lawsuit against EnzymeWorks and CEO Junhua â€œAlexâ€ Tao for Patent …” with publication date: February 22, 2016.
CDXS Company Profile
Codexis, Inc., incorporated on January 31, 2002, is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s technologies enable scale-up and implementation of biocatalytic solutions for process development, from research to manufacturing. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing clients to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Firm have commercialized its technology and products in the pharmaceuticals market, which is its primary business focus. The Company’s pharmaceutical customers, including several of the global pharmaceutical companies, use its technology, services and products in their manufacturing processes and process development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.